Previous 10 |
home / stock / paicw / paicw news
- Phase 2b study will investigate the efficacy of REVTx-99 on viral load and patient-reported flu symptoms- - Top-line data anticipated in the second quarter of 2022 - SAN DIEGO, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (Revelation), a clinical-stage life...
Revelation’s lead product candidate REVTx-99 has potential, through innate immune system stimulation, to broadly prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2 including its variants, influenza A and B, parainfluenza, rhinovirus, and resp...
News, Short Squeeze, Breakout and More Instantly...
Petra Acquisition Inc. Warrant Company Name:
PAICW Stock Symbol:
NASDAQ Market:
NEW YORK and SAN DIEGO, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Petra Acquisition, Inc. (NASDAQ: PAICU, PAIC, & PAICW) (“Perta”), a publicly traded special purpose acquisition company, announced today that it has entered into certain backstop agreements and forward share purchas...
-The Definitive Proxy Statement Has Been Filed with The Securities and Exchange Commission- -Stockholders Special Meeting Scheduled for January 6, 2022- NEW YORK and SAN DIEGO, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Petra Acquisition, Inc. (NASDAQ: PAICU, PAIC, & PAICW ...
- Dr. Bellanti is Director of the International Center for Interdisciplinary Studies of Immunology and Professor of Pediatrics and Microbiology and Immunology at Georgetown University SAN DIEGO, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (Revelation), a clinical...